See the DrugPatentWatch profile for Fondaparinux
How is Fondaparinux Administered?
Fondaparinux is administered subcutaneously, meaning it is injected just under the skin [1]. It is typically given once daily [1]. For patients with deep vein thrombosis (DVT) or pulmonary embolism (PE), the usual dose is 7.5 mg once daily [1]. For patients with overweight status (body weight greater than 100 kg), the dose is increased to 10 mg once daily [1]. For prophylaxis in patients undergoing hip fracture surgery or hip/knee replacement, the dose is 2.5 mg once daily, usually started 2-6 hours after surgery and continued for 5-8 days [1].
How Long Does Fondaparinux Treatment Last?
The duration of fondaparinux treatment varies depending on the condition being treated. For DVT and PE, treatment typically lasts for 4 to 5 days, after which patients are switched to an oral anticoagulant [1]. For extended prophylaxis after hip fracture surgery, treatment can continue for up to 24 days, for a total of up to 32 days [1].
Can Fondaparinux Be Given Intravenously?
While typically administered subcutaneously, fondaparinux can also be given intravenously for initial treatment of DVT or PE in certain situations, although subcutaneous administration is the standard [1].
What Are the Risks Associated with Fondaparinux?
The primary risk associated with fondaparinux is bleeding [1]. It can also increase the risk of spinal or epidural hematoma in patients undergoing spinal anesthesia or spinal puncture, potentially leading to long-term paralysis [1]. Another significant risk is a serious allergic reaction, including anaphylaxis, though this is rare [1].
Are There Alternatives to Fondaparinux?
Yes, there are several alternatives to fondaparinux for preventing and treating blood clots. These include unfractionated heparin, low molecular weight heparins (LMWHs) such as enoxaparin and dalteparin, and direct oral anticoagulants (DOACs) like rivaroxaban, apixaban, dabigatran, and edoxaban [2, 3]. The choice of anticoagulant depends on the patient's specific condition, risk factors, and physician's recommendation.
When Does Fondaparinux's Patent Protection End?
Information regarding the specific patent expiration dates for fondaparinux is not readily available in the provided context. However, patent information for pharmaceuticals can be complex, involving multiple patents covering the drug substance, formulations, and methods of use. Resources like DrugPatentWatch.com often track such patent landscapes [4].
Who Manufactures Fondaparinux?
Fondaparinux was originally developed by Leo Pharma and is marketed under the brand name Arixtra [5]. Generic versions are also available from various manufacturers.
What is the Mechanism of Action for Fondaparinux?
Fondaparinux is a synthetic pentasaccharide that selectively inhibits activated Factor X (Factor Xa) [1]. It does this by binding to antithrombin III, a natural anticoagulant in the blood, thereby accelerating the neutralization of Factor Xa [1]. By inhibiting Factor Xa, fondaparinux blocks the coagulation cascade, preventing the formation of thrombin and thus inhibiting clot formation [1].
What is the Clinical Data Supporting Fondaparinux Use?
Clinical trials have demonstrated the efficacy of fondaparinux in reducing the incidence of venous thromboembolism (VTE) in patients undergoing orthopedic surgery [1]. Studies have shown it to be effective in both preventing and treating DVT and PE [1].
---
Sources:
[1] https://www.drugs.com/fondaparinux.html
[2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4745063/
[3] https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.116.023159
[4] https://www.drugpatentwatch.com/
[5] https://www.ema.europa.eu/en/medicines/human/EPAR/arixtra